Oncology Venture gets option to in-license European rights to IXEMPRA
By Nikita Chaurasia  Date: 2019-04-05

Oncology Venture gets option to in-license European rights to IXEMPRA

Oncology Venture has reportedly gained an exclusive option to in-license the European rights to IXEMPRA® (ixabepilone) from the pharma company R-Pharm U.S., LLC. As per trusted sources, the aforesaid firm acquired global rights to IXEMPRA® from Bristol-Myers Squibb in July 2015 and the drug is permitted in the USA for the treatment of breast cancer.

Oncology Venture will assess ixabepilone along with its drug-specific DRP® companion diagnostic to obtain market approval in Europe.

According to a press release by Oncology Venture, the company has assessed the capacity of its DRP® companion diagnostic to detect which patients will most likely benefit from ixabepilone, depending on previous treatment results and information on tumor gene published by BMS in the scientific literature. The study specifies that patients profiting from Ixabepilone can be recognized through ixabepilone-specific DRP® companion diagnostic. Moreover, the company is certain that it will prevail in its quest to gain EMA approval in order to market ixabepilone across Europe to treat individuals with metastatic breast cancer.

As per the agreement, IXEMPRA® (ixabepilone) will undergo clinical trials in Europe with metastatic breast cancer patients, where the drug will be evaluated by Oncology Venture together with its DRP® companion diagnostic. If the trials unveil convincing results, Oncology Venture will have the option to in-license the commercial rights for IXEMPRA® in the European market. The extended pipeline is not anticipated to surge Oncology Venture’s cost base as the clinical development of ixabepilone will be funded via a special purpose vehicle/joint venture to be open to interested investors while the program will be controlled by Oncology Venture. 

For the record, ixabepilone was initially developed by Bristol-Myers Squibb and was permitted for the treatment of metastatic breast cancer by the US FDA in 2007 but failed to receive approval from the European Medicines Agency for the drug to be marketed in Europe. Currently, the product is marketed by R-Pharm in the USA, as well as in Switzerland, Lichtenstein and some parts of South America, reported sources.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Ikea buys Geomagical Labs to enhance AI-based visualization for users
Ikea buys Geomagical Labs to enhance AI-based visualization for users
By Nikita Chaurasia

Ikea, the leading home décor and furnishing giant, has recently acquired Geomagical Labs, which is a startup developing artificial intelligence-based imaging. Geomagical Labs has been developing various technologies based on computer vision t...

Insight unveils new Tech Journal for small & midmarket businesses
Insight unveils new Tech Journal for small & midmarket businesses
By Nikita Chaurasia

Insight Enterprises, a renowned US-based technology company and an integrator of the Insight Intelligent Technology SolutionsTM for companies of all sizes, reportedly unveiled a new magazine titled Tech Journal. This magazine would be published each...

Tesla CEO Elon Musk reveals plans to build ventilators for COVID-19
Tesla CEO Elon Musk reveals plans to build ventilators for COVID-19
By Nikita Chaurasia

U.S. auto giant Tesla, Inc.’s CEO, Elon Musk has recently made headlines when he announced that his company is planning to develop ventilators for COVID-19 patients. The move comes after the United States government’s latest appeal for do...

Google News launches Project Oasis to support local entrepreneurs
Google News launches Project Oasis to support local entrepreneurs
By Nikita Chaurasia

Google News has apparently launched Project Oasis in partnership with the University of North Carolina, Table Stakes co-founder Doug Smith, and LION Publishers. The partnership is aimed at helping the founders and aspiring founders of digital ne...

Pfizer collaborates with BioNTech to develop coronavirus vaccine
Pfizer collaborates with BioNTech to develop coronavirus vaccine
By Nikita Chaurasia

Increasing numbers of coronavirus cases worldwide have prompted researchers to develop a potential vaccine candidate to treat COVID-19 patients. Pfizer Inc., one of the leading American pharmaceutical companies, has reportedly collaborated with BioNT...